Volume : 08, Issue : 06, June – 2021

Title:

20.REVIEW ON HERBAL APPROACHES AND INVITRO AND INVIVO SCREENING METHODS OF ANTI-DIABETIC ACTIVITY

Authors :

Atluri Bhavana*, Divya Sree Ch, M. Navya, Bibi Rahamatha, Shaik Zahara, T. Bhavana, K. Padmalatha

Abstract :

Diabetes mellitus (DM), commonly known as just diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. Symptoms often include fatigue, frequent urination, increased thirst and increased appetite. If left untreated, diabetes can cause many health complications. Acute complications can include diabetes ketoacidosis, hyperosmolar hyperglycaemic shock, or death. Serious long-term complications include cardiovascular disease, stroke, chronic kidney damage, foot ulcers, damage to the nerves, damage to the eyes and cognitive impairment.
Diabetes is due to either the pancreasnot producing enough insulin, or the cells of the body not responding properly to the insulin produced. There are three main types of diabetes mellitus: Insulin-dependent diabetes mellitus (IDDM) or juvenile diabetes-Type-1 diabetes, non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes-Type-2 diabetes, Gestational diabetes.
In this review we discussed about the various in-vitro and animal models for the screening of anti-diabetic activity. These methods include chemical, genetic, surgical manipulations relevant to the human diabetics. A brief description of Chemical causes of diabetes, virus induced diabetes, hormone induced diabetes and various other methods along with in-vitro techniques are explained.
Keywords: Fatigue, Ketoacidosis, Gestational Diabetes, Genetic Manipulations.

Cite This Article:

Please cite this article in press Atluri Bhavana et al., Review On Herbal Approaches And In-vitro And Invivo Screening Methods Of Anti-Diabetic Activity.., Indo Am. J. P. Sci, 2021; 08(06).

Number of Downloads : 10

References:

[1] Ashcroft FM, Rorsman P (2004) Molecular defects in insulin secretion in type-2 diabetes. Rev EndocrMetabDisord 5: 135-142. 91. Affourtit C, Brand MD (2006) Stronger control of ATP/ADP by proton leak in pancreatic beta-cells than skeletal muscle mitochondria? The Biochemical Journal 393: 151-159
[2] Bedoya FJ, Solano F, Lucas M (1996) N-monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets. Experientia 52: 344-347.
[3] Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am 81: 527-542.
[4] Chattopadhyay S, Ramanathan M, Das J, Bhattacharya SK (1997) Animal models in experimental diabetes mellitus. Indian J Exp Biol 35: 1141-1145.
[5] Ebelt H, Peschke D, Bromme HJ, Morke W, Blume R, et al. (2000) Influence of melatonin on free radical-induced changes in rat pancreatic beta-cells in vitro. J Pineal Res 28: 65-72.
[6] Epand RM, Stafford AR, Tyers M, Nieboer E (1985) Mechanism of action of diabetogenic zinc-chelating agents. Model system studies. Mol Pharmacol 27: 366-374.
[7] Federiuk IF, Casey HM, Quinn MJ, Wood MD, Ward WK (2004) Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment. Comp Med 54: 252-257.
[8] Goldner MG, Gomori G (1944) Studies on the mechanism of alloxan diabetes. Endocrinol 35: 241-248.
[9] Grankvist K (1981) Alloxan-induced luminol luminescence as a tool for investigating mechanisms of radical-mediated diabetogenicity. Biochem J 200: 685-690.
[10] Hansotia T, Drucker DJ (2005) GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. RegulPept 128: 125- 134.
[11] https://en.wikipedia.org/wiki/Streptozotocin
[12] Iranloye BO, Arikawe AP, Rotimi G, Sogbade AO (2011) Anti-diabetic and anti-oxidant effects of Zingiberofficinale on alloxan-induced and insulin-resistant diabetic male rats. Nigerian journal of physiological sciences: official publication of the Physiological Society of Nigeria 26: 89-96.
[13] Jacobs HR (1937) Hypoglycemic action of alloxan. Proc Soc Exp Biol Med 37: 407-409. 15. Malaisse WJ, Malaisse-Lagae F, Sener A, Pipeleers DG (1982) Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci USA 79: 927-930.
[14] Jarvill-Taylor KJ, Anderson RA, Graves DJ (2001) A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. J Am Coll Nutr 20: 327-336.
[15] Katsumata K, Katsumata Y, Ozawa T, Katsumata K Jr (1993) Potentiating effects of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats. HormMetab Res 25: 125-126.
[16] Kliber A, Szkudelski T, Chichlowska J (1996) Alloxan stimulation and subsequent inhibition of insulin release from in situ perfused rat pancreas. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 47: 321-328.
[17] Kumar S, Singh R, Vasudeva N, Sharma S (2012) Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol 11: 9.
[18] Lelliott C, Vidal-Puig AJ (2004) Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. International Journal of Obesity and related Metabolic Disorders 28: 22-28.
[19] Lenzen S (2008) The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51: 216-226.
[20] Liu JP, Zhang M, Wang WY, Grimsgaard S (2004) Chinese herbal medicines for Type-2 diabetes mellitus. Cochrane Database Syst Rev: CD003642.
[21] Maddux BA, See W, Goldfine ID, Evans JL (2001) Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micromolar concentrations of alpha-lipoic acid? Diabetes 50: 404-410.
[22] Masiello P (2006) Animal models of Type-2 diabetes with reduced pancreatic beta-cell mass. Int J Biochem Cell Biol 38: 873-893.
[23] Morgan NG, Cable HC, Newcombe NR, Williams GT (1994) Treatment of cultured pancreatic B-cells with streptozotocin induces cell death by apoptosis. Biosci Rep 14: 243-250.
[24] Munday R (1988) Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of “active oxygen” species. BiochemPharmacol 37: 409-413.
[25] Nukatsuka M, Yoshimura Y, Nishida M, Kawada J (1990) Importance of the concentration of ATP in rat pancreatic beta cells in the mechanism of streptozotocin-induced cytotoxicity. J Endocrinol 127: 161-165.
[26] Park BH, Rho HW, Park JW, Cho CG, Kim JS, et al. (1995) Protective mechanism of glucose against alloxan-induced pancreatic beta-cell damage. BiochemBiophys Res Commun 210: 1-6.
[27] Ramachandran S, Rajasekaran A, Adhirajan N (2013) In Vivo and In Vitro Antidiabetic Activity of Terminalia paniculata Bark: An Evaluation of Possible Phytoconstituents and Mechanisms for Blood Glucose Control in Diabetes. ISRN Pharmacol 2013: 484675.
[28] Sandler S, Swenne I (1983) Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro. Diabetologia 25: 444-447.
[29] Sangeetha R, Vedasree N (2012) In VitroAmylase Inhibitory Activity of the Leaves of Thespesia populnea. See comment in PubMed Commons below ISRN Pharmacol 2012: 515634.
[30] Storling J, Zaitsev SV (2005) Calcium has a permissive role in interleukin-1 induced c-jun N-terminal kinase activation in insulinsecreting cells? Endocrinology 146: 3026-3036.
[31] Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 537-546.
[32] Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel ML (1993) Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. BiochemBiophys Res Commun 197: 1458-1464.
[33] Unite for diabetes (2011) One adult in ten will have diabetes by 2030. 5th edn. International diabetes federation.
[34] West E, Simon OR, Morrison EY (1996) Streptozotocin alters pancreatic beta-cell responsiveness to glucose within six hours of injection into rats. West Indian Med J 45: 60-62. 13. Tasaka Y, Inoue Y, Matsumoto H, Hirata Y (1988) Changes in plasma glucagon, pancreatic polypeptide and insulin during development of alloxan diabetes mellitus in dog. Endocrinol Jpn 35: 399-404.
[35] Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
[36] Wrenshall GA, Collins-Williams J, Best CH (1950) Initial changes in the blood sugar of the fasted anesthetized dog after alloxan. Am J Physiol 160: 228-246.
[37] Zhao YF, Keating DJ, Hernandez M, Feng DD, Zhu Y (2005) Long-term inhibition of protein tyrosine kinase impairs electrophysiology activity and a rapid component of exocytosis in pancreatic cells. Journal of Molecular Endocrinology 35: 49-59.